Orgenesis Inc. (ORGS) Research

Orgenesis Inc. is a global biotechnology firm dedicated to the field of cell and gene therapies. The company has engineered an innovative Point of Care (POCare) platform. This system incorporates a portfolio of licensed POCare therapeutics, which are manufactured and prepared using automated, self-contained POCare technology within a cooperative network. Orgenesis primarily concentrates on autologous therapies, developing customized processes and systems for each treatment. These utilize a closed, automated processing methodology, validated for safe and compliant production directly at the patient's location, facilitating immediate therapeutic application. Established in 2008 as Business Outsourcing Service, Inc., the company adopted the name Orgenesis Inc. in August 2011 and is headquartered in Germantown, Maryland.

Market snapshot

Symbol
ORGS
Price
$0.32
Day change
-7.37%
Market cap
$1.6M
P/E ratio
-0.17x
52-week range
0.02-5.89
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Bio-Path Holdings, Inc. (BPTH)
  • Emmaus Life Sciences, Inc. (EMMA)
  • Helix BioMedix, Inc. (HXBM)
  • Indocan Resources Inc. (IDCN)
  • Next Generation Management Corp. (NGMC)
  • Neutra Corp. (NTRR)
  • Paion AG (PAIOF)
  • SQZ Biotechnologies Company (SQZB)

Recent insider activity

  • MALIK ARIEL — trade (0 shares) on 2025-03-05
  • Adler Yaron — A-Award (1750 shares) on 2024-12-12
  • PELAVIN ADAM — A-Award (1250 shares) on 2024-12-12
  • PELAVIN ADAM — A-Award (625 shares) on 2024-12-12
  • Nanda Ashish — A-Award (1835 shares) on 2024-12-12

Open Orgenesis Inc. (ORGS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.